Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis-Reference-Cited by-同舟云学术

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

Published:2006 Issue:1 Volume:56 Page:311-322
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Distler Jörg H. W.,Jüngel Astrid,Huber Lars C.,Schulze-Horsel Ursula,Zwerina Jochen,Gay Renate E.,Michel Beat A.,Hauser Thomas,Schett Georg,Gay Steffen,Distler Oliver

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference34 articles.

1. Pathologic observations in systemic sclerosis (scleroderma)

2. CARBOXYTERMINAL TYPE I PROCOLLAGEN PEPTIDE CONCENTRATIONS IN SYSTEMIC SCLEROSIS: HIGHER LEVELS IN EARLY DIFFUSE DISEASE

3. Mortality and causes of death in a Swedish series of systemic sclerosis patients

4. Regulation of Connective Tissue Synthesis in Systemic Sclerosis

5. Immunohistologic Demonstration of Platelet-derived Growth Factor (PDGF) and sis-Oncogene Expression in Scleroderma

Cited by 338 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of a pH-responsive imatinib mesylate sustained-release hydrogel for the treatment of tendon adhesion by inhibiting PDGFRβ/CLDN1 pathway;Bioactive Materials;2024-08

2. Cluster of differentiation molecules in the metabolic syndrome;Clinica Chimica Acta;2024-07

3. Perspective to precision medicine in scleroderma;Frontiers in Immunology;2024-01-18

4. Recent Advances in Treatment of Systemic Sclerosis and Morphea;American Journal of Clinical Dermatology;2023-12-12

5. ACSL4 inhibition prevents macrophage ferroptosis and alleviates fibrosis in bleomycin-induced systemic sclerosis model;Arthritis Research & Therapy;2023-10-26